Adaptive Biotechnologies Corporation (ADPT) vs CRISPR Therapeutics AG (CRSP)
A side-by-side comparison of Adaptive Biotechnologies Corporation and CRISPR Therapeutics AG across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ADPT
Adaptive Biotechnologies Corporation
$27.61HealthcareDelayed quote: Oct 6, 2026, 11:31 AM EDT
CRSP
CRISPR Therapeutics AG
$54.78HealthcareDelayed quote: Oct 6, 2026, 11:31 AM EDT
Total return — ADPT vs CRSP
growth of $100 · dividends reinvested · last 7yADPT -26.0% (-4.2%/yr)CRSP +26.4% (+3.4%/yr)CRSP compounded faster over this window
ADPT CRSP
ADPT vs CRSP: by the numbers
- •CRSP is the larger company ($5.28B vs $4.42B market cap).
- •Both run net losses; ADPT's is the smaller (-20.73% vs -3368.72% net margin).
- •CRSP grew revenue faster over the past five years (37.32% vs 18.22% CAGR).
Metrics side by side
Valuation
| Metric | ADPT | CRSP |
|---|---|---|
| P/S ratio | 14.34 | 394.54 |
| P/B ratio | 30.92 | 3.03 |
Profitability
| Metric | ADPT | CRSP |
|---|---|---|
| Gross margin | 75.44% | -6537.01% |
| Operating margin | -20.62% | -16191.40% |
| Net margin | -20.73% | -3368.72% |
| ROE | -44.68% | -25.83% |
| ROIC | -6.67% | -21.12% |
Growth (annualized)
| Metric | ADPT | CRSP |
|---|---|---|
| Revenue CAGR (5Y) | 18.22% | 37.32% |
| Total return CAGR (5Y) | -1.77% | -10.97% |
Frequently asked
- Which has grown faster, ADPT or CRSP?
- Over the past five years, CRSP grew revenue faster — ADPT at a 18.22% CAGR versus CRSP at 37.32%.
- How have ADPT and CRSP total returns compared?
- Over the past 5 years, ADPT delivered -1.77% and CRSP delivered -10.97% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Adaptive Biotechnologies ROECRISPR Therapeutics AG ROEAdaptive Biotechnologies operating marginCRISPR Therapeutics AG operating marginAdaptive Biotechnologies revenue growthCRISPR Therapeutics AG revenue growthAdaptive Biotechnologies free cash flowCRISPR Therapeutics AG free cash flow
Adaptive Biotechnologies & CRISPR Therapeutics AG appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.